The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 760K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

20 articles for A Thorarensen


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
9
Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.EBI
Pfizer
20
3-Arylpiperidines as potentiators of existing antibacterial agents.EBI
Pharmacia
9
Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode.EBI
Pfizer
10
Conformational Role of Methyl in the Potency of Cyclohexane-Substituted Squaramide CCR6 Antagonists.EBI
Pfizer Inc.
1
Human serum albumin binding assay based on displacement of a non selective fluorescent inhibitor.EBI
Pharmacia
1
Preparation of novel anthranilic acids as antibacterial agents: extensive evaluation of structural and physical properties on antibacterial activity and human serum albumin affinity.EBI
Pharmacia
14
Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition.EBI
Pharmacia
18
Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.EBI
Pfizer
31
Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.EBI
Karo Pharma
30
Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.EBI
Pfizer
2
INHIBITORS OF CHYMASE FOR USE IN THE SELECTIVE RESOLUTION OF THROMBI IN THROMBOTIC OR THROMBOEMBOLIC DISORDERSBDB
Socpra Sciences Sante Et Humaines S.E.C.
16
SUBSTITUTED FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOFBDB
Suzhou Yabao Pharmaceutical R&D
22
BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDSBDB
Lycia Therapeutics
3
SUBSTITUTED TRICYCLIC COMPOUND AS PRMT5 INHIBITOR AND USE THEREOFBDB
NANJING SANHOME PHARMACEUTICAL CO., LTD.
20
Inhibitors of bruton's tyrosine kinaseBDB
Hoffmann-La Roche
267
Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBDB
Boehringer Ingelheim International
34
Overview of the SAMPL5 host-guest challenge: Are we doing better?BDB
University of California San Diego
87
5-substituted indazoles as kinase inhibitorsBDB
Abbvie
42
Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.BDB
University of Massachusetts Medical School